EIF2A and cancer: Targeting the PERK/eIF2α axis accelerates cell death of therapy-resistant colon carcinoma cells and hypoxic glioblastoma [260], raising the possibility that a combination of cancer therapy and UPR targeting may be a promising strategy for cancer treatment.